Sequent Scientific Limited has informed the Exchange about Investor Presentation

Proven Ability In Life Sciences

November 18, 2025

To, BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai - 400 001

National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051

Scrip code: 512529

Scrip code: SEQUENT

Dear Sir/ Madam,

Subject: Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Ref: Composite scheme of amalgamation amongst Sequent Scientific Limited (“Company”), Symed Labs Limited, Vandana Life Sciences Private Limited, Appcure Labs Private Limited, Vindhya Pharma (India) Private Limited, S.V. Labs Private Limited, Vindhya Organics Private Limited, Viyash Life Sciences Private Limited, Geninn Life Sciences Private Limited, Sequent Research Limited and their respective shareholders and the creditors (“Scheme”)

With reference to the above, and in furtherance of our previous disclosures dated September 26, 2024, January 21, 2025, May 26, 2025, and August 30, 2025, we would like to inform you that the Hon’ble National Company Law Tribunal, Hyderabad Bench (“Hon’ble Tribunal”) has at the hearing held today i.e. November 18, 2025 allowed the petition and pronounced the order for sanctioning the Scheme.

A written order of the Hon’ble Tribunal sanctioning the Scheme (“Order”) is awaited and will be disclosed upon the Order becoming available on the website of the Hon’ble Tribunal.

The companies involved in the Scheme shall take necessary actions in accordance with the Scheme to make the Scheme effective. The Company shall inform the relevant dates under the Scheme, including the Effective Date 1 and Effective Date 2 (as defined in the Scheme) in due course for further public dissemination in accordance with applicable law and as and when the conditions for effectiveness are fulfilled. The Appointed Date of the Scheme is April 1, 2025.

Pursuant to the above, please find enclosed herewith Press Release and an updated version of the Investor Presentation shared by the Company.

Kindly take the same on record.

Thanking you,

Yours faithfully, For Sequent Scientific Limited

Yoshita Vora Company Secretary & Compliance Officer Encl: As above

Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39, Guttala Begumpet, Jubilee Hills, Hyderabad - 500033, Telangana

Office: 301, 3rd Floor, Dosti Pinnacle, Plot No. E7, Road No. 22, Wagle Industrial Estate, Thane (W), Mumbai - 400604, Maharashtra

SeQuent Scientific Limited

Tel No.: +91 9391139986 / 22-4111 4777 I CIN: L99999TS1985PLC196357 Website: http://www.sequent.in I Email Id: investorrelations@sequent.in

Press Release

SeQuent Scientific and Viyash Lifesciences Receive NCLT Approval for Transformational Merger

• Combined Strengths Poised to Create a Global Animal Health Powerhouse • Q2 FY25–26: Combined Sales Up 16%, EBITDA Surges 76%, underscoring the

operational and strategic synergies emerging from the merger

Mumbai, 18 November 2025 : SeQuent Scientific Ltd. (“SeQuent”), a leading player in the global Animal Health industry, and Viyash Lifesciences Private Limited (“Viyash”), an integrated global pharmaceutical company, announced today that the National Company Law Tribunal (NCLT) has allowed the petition and approved the Scheme of merger between SeQuent and the Viyash group of companies. The NCLT approval marks the beginning of a new chapter for the combined entity, and represents a fundamental transformation to leapfrog into the next orbit of the global animal health market. The combined financial performance of the companies with aggregate H1FY26 revenues of INR 16.5bn and aggregate H1FY26 EBITDA of INR 3.2bn, with a Net Debt to EBITDA ratio of 0.7x, represents significant scale as the largest animal health player from India.

As highlighted earlier, the combined entity is aligned to capitalise on two major long-term industry opportunities:

1. Global, fast-growing Companion (Pet) Animal Health segment – The inherent growth in the market provides a large opportunity, driven by increased pet adoption and emerging treatments for Bone & Joint disease, Dermatitis, Diabetes, Cardiology and Oncology, similar to human pharmaceutical applications.

2. Genericization of Animal Health, which lags significantly behind Human Health – This provides a substantial opportunity for the combined company to leverage its technical strengths in APIs and Formulations. In addition, the advanced capabilities in R&D would help strengthen its fast- growing CDMO business.

This merger not only delivers the necessary scale and capabilities for accelerating organic growth in the Animal Health market, but also provides financial resilience, stability, and management bandwidth to rejuvenate SeQuent’s inorganic growth engine.

Dr. Haribabu Bodepudi, Founder and CEO, Viyash, said, “This merger creates the platform to deliver world-class solutions for our customers. With our strengths in R&D, custom development capabilities, manufacturing capacities, and a streamlined supply chain, we would emerge as an innovative and reliable partner for our customers across the world. Over the last few months, we have developed a comprehensive plan for integration which leverages synergies for growth and capability. The momentum reflected in our recent results is only the beginning”

Commenting on the merger, Mr. Rajaram Narayanan, Managing Director and CEO of SeQuent, said, “We are pleased to receive the approval from the Hon’ble NCLT, marking the start of a transformative journey for the combined entity. There are significant opportunities to provide relevant, differentiated and quality care for animals. With this merger, the Company will be uniquely positioned to build a world-class business and deliver on the requirements of pet owners, farmers and animal health professionals. Together, we are building a company that will set new benchmarks in quality, innovation, and customer trust.”

About SeQuent Scientific

SeQuent Scientific Limited (BSE: 512529, NSE: SEQUENT), headquartered in India, operates in the Animal Health market with a global footprint. SeQuent has seven manufacturing facilities based in India, Spain, Brazil and Turkey with approvals from international regulatory bodies, including USFDA, EUGMP, WHO, TGA, etc. SeQuent currently produces APIs and animal health formulations in over 100 countries and has more than 1,500 employees.

About Viyash Lifesciences

Viyash Lifesciences is an integrated end-to-end pharmaceutical company with a presence across niche formulations, APIs and advanced intermediates. Viyash has an R&D team of 200+ scientists and has 9 USFDA-approved plants, signifying strong R&D and manufacturing capabilities. Viyash serves customers across 150+ countries.

For further information, please contact:

Yoshita Vora Company Secretary SeQuent Scientific Limited Email: investorrelations@sequent.in

Janaki S Company Secretary Viyash Lifesciences Private Limited

Abhishek Singhal Investor Relations Consultant Email: abhishek@arunya.co.in

INVESTOR PRESENTATION Q2 FY26

S E Q U E N T S C I E N T I F I C L I M I T E D

18th Nov 2025

Steadfast commitment to improvement in business fundamentals

“The results of Q2 FY 25-26 and the first half FY 25-26 reinforce the transformational journey

undertaken by the company. Revenue, margins and profits have continued to show healthy

growth on the back of new product

introductions, superior product mix and cost

improvement programs. The merger with Viyash Life Sciences is almost concluded. We are

already seeing the benefits in manufacturing synergies, R&D programs and customer leads.

Viyash continues to deliver market beating performance in new filings, sales and margins.

The merged entity is now well positioned to build new revenue streams, in addition to

accelerating growth of existing businesses.”

Rajaram Narayanan Sequent Scientific Limited

Dr Hari Babu Bodepudi Viyash Life Sciences Limited

Q2FY26 Combined Performance

Q2 FY26 Performance Highlights

Revenues

EBITDA1

EBITDA margin

Net Debt to LTM EBITDA1

₹8,521 Million

₹1,890 Million

22.2%

0.7x

+16 % YoY

+76% YoY

+750 bps YoY

1.4x in Q2 FY25

Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs. 2. Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

4

Broad based revenue growth across all businesses

All values in ₹ Mn

Revenue Distribution

Q2 FY26

Q2 FY25

YoY Gr%

Q1 FY26

QnQ Gr%

H1 FY26

H1 FY25

YoY Gr%

Formulations

Europe

Emerging Markets

India

APIs

Other Sales

Global Sales

One Offs #

3,364

1,533

1,469

362

830

13

2,836

1,335

1,160

341

773

22

18.6%

14.8%

26.7%

6.2%

7.3%

(40.7%)

3,383

1,640

1,480

263

1,054

15

(0.5%)

(6.5%)

(0.7%)

37.8%

6,747

3,172

2,949

625

(21.3%)

1,884

5,837

2,910

2,342

585

1,697

15.6%

9.0%

25.9%

6.8%

11.0%

(10.3%)

28

64

(56.5%)

4,207

3,631

15.9%

4,451

(5.5%)

8,659

7,598

14.0%

Adjustment* - Ind AS 29*

Sequent Sales

Viyash Sales

Overall Sales

33

4,240

4,281

8,521

13

43

3,686

3,632

7,319

15.0%

17.8%

16.4%

(56)

19

4,414

3,527

7,941

-56

51

8,654

7,808

-74

64

7,589

7,032

(3.9%)

21.4%

7.3%

16,462

14,621

*Adjustment on account of hyperinflation in Turkey as per Ind AS 29

# Provision for customer claim on shipments in prior years

Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments

14.0%

11.0%

12.6%

5

H1 FY26 Performance Highlights

Revenues

EBITDA1

EBITDA margin

All values in ₹ Mn

Net Debt to LTM EBITDA1

₹16,462 Million

₹3,180 Million

19.3%

0.7x

+12.6 % YoY

+48% YoY

+460 bps YoY

1.4x in H1 FY25

Notes: 1. EBITDA for Viyash and SeQuent are adjusted for ESOP costs 2. Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

6

Combined P&L Snapshot

Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments 1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash) 2. PAT adjusted for Amortization of acquisition intangibles and Minority 3.Adjusted for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

7

Combined Balance Sheet Snapshot

Particulars

Shareholders' Funds Minority Interest Net Debt Other Non current Liabilities Total Liabilities Tangible Assets Intangible Assets Goodwill Working Capital Other Non current Asset Net assets held for Sale Total Assets

All values in ₹ Mn

Combined As of 30 Sep 2025 26,146 1,674 4,095 2,362 34,276 11,930 1,485 8,303 9,672 2,609 277 34,276

Key Ratios

Combined

Net Debt to Equity Net Debt to EBITDA RoCE ex Goodwill (%) RoE ex-Goodwill (%)

0.2x 0.7x 13% 13%

Note: Financials presented are Pro forma financials (unaudited) for guidance on combined performance without incorporating any merger-related adjustments 1. Exceptional Items include cost of accelerated vesting for share warrants, call option charge, merger expenses (Viyash) and one-time contractual bonus payable to Viyash management (Viyash) 2. PAT adjusted for Amortization of acquisition intangibles and Exceptional Items (net of tax) 3.Adjusted for ESOP costs Source: Viyash Life Sciences website published Investor Presentation for Viyash numbers

8

Merger Update

Merger – Process Update

Merger process status update

• NCLT approval order reserved on Oct 31, 2025;

order pronounced on Nov 18, 2025

• Focus on synergy realization for next 12 months

10

Synergy Update

In advanced stages

11

New production block commissioned in record time

New production block created in short time to improve capacity, productivity and cost of Sequent products

One large volume Sequent API validated & filing under progress

12

Business Update - Sequent

SeQuent: Q2FY26 Business Performance

All values in ₹ Mn

Formulations

Europe: Significant growth in Spain with good exports performance

Emerging Markets:

 Launched Tulaject in Brazil & received MA for Mexico market  R&D infrastructure expanded

India: Business beginning to accelerate as field team expansion ramps up

Business momentum continues, ~7% YoY growth

Launched a product for the US market

API

Completed successful audits for a large customers with no critical

observations

SRL USFDA audit completed – EIR awaited

1,000+ FDFs

90+ Countries

5 Manufacturing Facilities

35 APIs

50+ Countries

2 Manufacturing facilities

Business Update - Viyash

Viyash: Q2 FY26 Key growth drivers

New products launches

Focus on CDMO business

Improved product mix

Network optimisation for better efficiencies

Backward and Forward integration

16

Key updates from Q2 FY26

Facility Inspections

4 Regulatory Audits 56 Customer audits 1 US FDA EIR

Regulatory Approvals

Launches

2APIs: (USDMF-1 ; EDQM-1

2 FDFs (US) 2 APIs

Products Filed

Validations Completed

R&D Pipeline

9 Filings – SFDA(3), EDQM (1) TGA (1), EDMF (2), WHO (1), TW (1) FDFs -Nil

Source: Viyash Life Sciences website published Investor Presentation

3 APIs

16+ Products

17

For details, feel free to contact:

Yoshita Vora

Company Secretary

+91 22 4111 4777

investorrelations@sequent.in

Abhishek Singhal

Investor Relations Consultant

abhishek@arunya.co.in

Registered Office: 3rd Floor, Srivalli’s Corporate, Plot No. 290, SYN 33 34P TO 39,

Guttala Begumpet, Jubilee Hills, Shaikpet, Hyderabad-500033, Telangana

Websites: www.sequent.in, www.alivira.co | CIN: L99999TS1985PLC196357 | BSE Code:512529 | NSE: SEQUENT

ISIN: INE807F01027

Certain statements in this document that are not historical facts are forward looking statements. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local, political or economic developments, technological risks, and many other factors that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. SeQuent Scientific Ltd. will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

18

Thank You